Literature DB >> 22001121

Guillain-Barré Syndrome in India: population-based validation of the Brighton criteria.

Farrah J Mateen1, David R Cornblath, Hamid Jafari, Russell T Shinohara, Devendra Khandit, Bina Ahuja, Sunil Bahl, Roland W Sutter.   

Abstract

OBJECTIVE: Case definitions of GBS were recently developed in response to the 2009 H1N1 vaccination programme but have undergone limited field testing. We validate the sensitivity of the Brighton Working Group case definitions for Guillain-Barré Syndrome (GBS) using a population-based cohort in India.
METHODS: The National Polio Surveillance Unit of India actively collects all cases of acute flaccid paralysis (AFP) in children <15 years old, including cases of GBS. Cases of GBS with available cerebrospinal fluid (CSF) and nerve conduction studies (NCS) results, neurological examination, clinical history, and exclusion of related diagnoses were selected (2002-2003). Relevant data were abstracted and entered into a central database. Sensitivity of the Brighton GBS criteria for level 3 of diagnostic certainty which requires no clinical laboratory testing, level 2 which employs CSF or NCS, and level 1 which employs both, were calculated.
RESULTS: 79 cases of GBS (mean age 6.5 years, range 4.0-14.5; 39% female) met the case definition. GBS cases were ascending (79%), symmetrical (85%), and bilateral (100%); involving lower extremity hypotonia (86%) and weakness (100%), upper extremity hypotonia (62%) and weakness (80%), areflexia/hyporeflexia (88%), respiratory muscles (22%), bulbar muscles (22%), and cranial nerves (13%). Four limbs were involved in 80% of cases. Mean time to maximal weakness was 5.2 days (range 0.5-30 days) with nadir GBS disability scores of 3 (7%), 4 (67%), 5 (15%), 6 (10%), or unclear (1%). CSF (mean time to lumbar puncture 29 days) was normal in 29% with cytoalbuminologic dissociation in 65% (mean protein 105 mg/dL, range 10-1000; mean cell count 11/μL, range 0-220, n=4 with >50 cells/μL). Significant improvement occurred in 73% whereas death (9%) occurred 6-29 days after sensorimotor symptom onset. The majority of cases (86%) fulfilled Brighton level 3, level 2 (84%), and level 1 (62%) of diagnostic certainty.
CONCLUSION: The diagnosis of GBS can be made using Brighton Working Group criteria in India with moderate to high sensitivity. Brighton Working Group case definitions are a plausible standard for capturing a majority of cases of GBS in field operations in low income settings during AFP surveillance.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22001121      PMCID: PMC3638251          DOI: 10.1016/j.vaccine.2011.09.123

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

1.  Outcomes in the Guillain Barre syndrome: the role of steroids.

Authors:  J V Peter; C Gnanamuthu; A M Cherian; S Prabhakar
Journal:  J Assoc Physicians India       Date:  1996-03

2.  Surveillance of acute flaccid paralysis in India.

Authors:  Paul T Francis
Journal:  Lancet       Date:  2007-04-21       Impact factor: 79.321

Review 3.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

4.  Landry-Guillain-Barré-Strohl syndrome in India.

Authors:  P N Chhuttani; L S Chawla; K S Chugh; H Singh
Journal:  J Neurol Sci       Date:  1968 Nov-Dec       Impact factor: 3.181

Review 5.  Guillain-Barré syndrome.

Authors:  Richard A C Hughes; David R Cornblath
Journal:  Lancet       Date:  2005-11-05       Impact factor: 79.321

6.  Guillain-Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition.

Authors:  Young June Choe; Heeyeon Cho; Geun-Ryang Bae; Jong-Koo Lee
Journal:  Vaccine       Date:  2011-01-19       Impact factor: 3.641

7.  Fatal Guillain-Barré syndrome after the national influenza immunization program.

Authors:  R A Keenlyside; L B Schonberger; D J Bregman; J Z Bolyai
Journal:  Neurology       Date:  1980-09       Impact factor: 9.910

8.  Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies.

Authors:  T W Ho; B Mishu; C Y Li; C Y Gao; D R Cornblath; J W Griffin; A K Asbury; M J Blaser; G M McKhann
Journal:  Brain       Date:  1995-06       Impact factor: 13.501

9.  Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

Authors:  R D Hadden; D R Cornblath; R A Hughes; J Zielasek; H P Hartung; K V Toyka; A V Swan
Journal:  Ann Neurol       Date:  1998-11       Impact factor: 10.422

10.  Guillain-Barré syndrome. A prospective clinical study in 25 children and comparison with adults.

Authors:  C Sarada; J K Tharakan; M Nair
Journal:  Ann Trop Paediatr       Date:  1994
View more
  12 in total

Review 1.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

2.  Rate of progression of Guillain-Barré syndrome is not associated with the short-term outcome of the disease.

Authors:  Mirjana Arsenijević; Ivana Berisavac; Branka Mladenović; Predrag Stanarčević; Dejana Jovanović; Dragana Lavrnić; Stojan Peric
Journal:  Ir J Med Sci       Date:  2020-07-14       Impact factor: 1.568

3.  Diagnosing SARS-CoV-2 associated Guillain-Barre syndrome requires cerebro-spinal-fluid studies.

Authors:  Josef Finsterer; Fulvio A Scorza; Carla A Scorza; Ana C Fiorini
Journal:  J Neuroimmunol       Date:  2021-05-13       Impact factor: 3.478

4.  Diagnosis of Guillain-Barré syndrome in children and validation of the Brighton criteria.

Authors:  Joyce Roodbol; Marie-Claire Y de Wit; Bianca van den Berg; Vivienne Kahlmann; Judith Drenthen; Coriene E Catsman-Berrevoets; Bart C Jacobs
Journal:  J Neurol       Date:  2017-03-01       Impact factor: 4.849

5.  Significance of Brighton Criteria in the Early Diagnosis and Management of Guillain-Barré Syndrome.

Authors:  Haider Ghazanfar; Rabia Qazi; Ali Ghazanfar; Sania Iftekhar
Journal:  Cureus       Date:  2020-05-27

6.  Clinical Profile, Functional Outcome, and Mortality of Guillain-Barre Syndrome: A Five-Year Tertiary Care Experience from Nepal.

Authors:  Saroj Kumar Bhagat; Shrey Sidhant; Mukesh Bhatta; Ashish Ghimire; Bhupendra Shah
Journal:  Neurol Res Int       Date:  2019-06-02

7.  Causes of albuminocytological dissociation and the impact of age-adjusted cerebrospinal fluid protein reference intervals: a retrospective chart review of 2627 samples collected at tertiary care centre.

Authors:  John Alexander Brooks; Christopher McCudden; Ari Breiner; Pierre R Bourque
Journal:  BMJ Open       Date:  2019-02-13       Impact factor: 2.692

Review 8.  Guillain-Barré syndrome in low-income and middle-income countries: challenges and prospects.

Authors:  Nowshin Papri; Zhahirul Islam; Sonja E Leonhard; Quazi D Mohammad; Hubert P Endtz; Bart C Jacobs
Journal:  Nat Rev Neurol       Date:  2021-03-01       Impact factor: 42.937

9.  Detection of diphtheritic polyneuropathy by acute flaccid paralysis surveillance, India.

Authors:  Farrah J Mateen; Sunil Bahl; Ajay Khera; Roland W Sutter
Journal:  Emerg Infect Dis       Date:  2013       Impact factor: 6.883

10.  A follow-up study on Guillain-Barre syndrome and validation of Brighton criteria.

Authors:  Reza Boostani; Farveh Ramezanzadeh; Morteza Saeidi; Mina Khodabandeh
Journal:  Iran J Neurol       Date:  2019-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.